<p>Clinical outcome of <em>Escherichia coli</em> bloodstream infection in cancer patients with/without biofilm formation: a single-center retrospective study</p>

Abstract

<i>bla</i> _CTX-M-15 type ESBL-EC is highly endemic among cancer patients with BSI. BF is associated with multi-drug resistance by ESBL-EC and is also an independent risk factor of mortality for cancer patients with BSI. Our findings suggest that the combination of BF-positive ESBL-EC isolates with other appropriate laboratory indicators might benefit infection control and improve clinical outcomes.